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INTRAVITREAL INJECTION OF PERFLUOROPROPANE 
IS MORE EFFICACIOUS THAN SULFUR HEXAFLUORIDE 
IN RELEASING VITREOMACULAR TRACTION
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SUMMARY – Th e aim was to compare the effi  cacy of a single intravitreal injection of perfl uoro-
propane (C3F8) and sulfur hexafl uoride (SF6) in releasing vitreomacular traction (VMT). Th is pro-
spective study included two groups of patients with symptomatic VMT confi rmed by spectral-domain 
optical coherence tomography (SD-OCT). Patients from both groups received a single intravitreal 
injection of expansile gas. One group (29 eyes) received 0.3 mL of 100% C3F8, and the other group 
(28 eyes) received 0.3 mL of 100% SF6. Eyes without VMT release one month after SF6 injection 
were secondarily injected with C3F8. Th e primary outcome was the ratio of eyes in each group with 
complete VMT release on OCT one month following primary treatment. Th e secondary outcome was 
the ratio of reinjected eyes with complete VMT release on OCT one month following second injec-
tion. Additional outcome was the ratio of VMT release in eyes with specifi c clinical characteristics. 
One month after the application, complete release of VMT on OCT was recorded in 18 out of 29 eyes 
(62%) in the C3F8 group, in 6 out of 28 eyes (21.4%) in the SF6 group, and in 7 out of 14 (50%) 
 reinjected eyes. Th ere was no statistically signifi cant diff erence in age, width of vitreomacular attach-
ment (WVMAT), central retinal thickness and presence of additional features between the two 
groups. In eyes with WVMAT <500 microns, there was no statistically signifi cant diff erence between 
the two gases in releasing VMT. In eyes with WVMAT >500 microns, C3F8 was more effi  cacious 
(p=0.001). According to the results of our study, intravitreal C3F8 injection seems to be more effi  ca-
cious in releasing VMT than SF6 in eyes with WVMAT larger than 500 microns.
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Introduction
Vitreoretinal interface diseases are thought to oc-
cur due to an anomalous or incomplete posterior vitre-
ous detachment (PVD), i.e. separation of the vitreous 
cortex from the internal limiting membrane. In 2013, 
the International Vitreomacular Traction Study Group 
defi ned and classifi ed vitreoretinal interface diseases 
according to optical coherence tomography (OCT)-
based anatomic fi ndings in vitreomacular adhesion 
(VMA), vitreomacular traction (VMT) and macular 
hole1. VMA was defi ned as perifoveal vitreous separa-
tion with the remaining vitreomacular attachment and 
unperturbed foveal morphological features. It is an 
OCT fi nding that is almost always the result of nor-
mal vitreous aging1. VMT is characterized by anoma-
lous posterior vitreous detachment accompanied by 
anatomic distortion of the fovea, which may include 
pseudocysts, macular schisis, cystoid macular edema, 
and subretinal fl uid1. Primary full-thickness macular 
hole (FTMH) was defi ned as a foveal lesion with in-
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terruption of all retinal layers from the internal limit-
ing membrane to the retinal pigment epithelium, 
caused by vitreous traction1.
Anatomical changes of the fovea induced by VMT 
can lead to typical symptoms of reduced visual acuity, 
decreased reading vision, metamorphopsia, and mi-
cropsia. Th e natural history of patients with VMT is 
not well established, but it is thought that 11%-40% of 
symptomatic VMT dissolve spontaneously in 8-12 
months, although restoration of foveal anatomy is un-
certain2. Other symptomatic patients with persistent 
VMT may undergo further progression into macular 
hole, persistent macular edema, foveal detachment, 
macular atrophy, and severe deterioration of visual 
function and quality of life3-5.
Th e standard treatment for severe VMT is pars 
plana vitrectomy. Th e goal of vitreous surgery is to 
eliminate anteroposterior and tangential traction, 
thereby relieving attachment of the vitreous to the 
macula. Vitreolysis is achieved in 100% of cases, with 
good anatomical outcome and some improvement of 
vision in most cases6, but the surgery itself is not with-
out risk. Intraoperative retinal tears occur in up to 
1.6% and postoperative retinal detachment in up to 
Table 1. Studies investigating the effi  cacy of intravitreal SF6 or C3F8 injection in causing PVD in eyes with diff erent 
pathologies
















0.5 mL 100% 
SF6
20 100% No complications






0.3 mL 100% 
SF6
9 56% Peripheral retinal 
tear in 1 patient 
(11%)
Total   SF6  29 78%
Complication 






















0.3 mL 100% 
C3F8
5 100% Vitreous hemorrhage 











23 96% Peripheral retinal 











0.3 mL 100% 
C3F8









VMT 0.3 mL 100% 
C3F8
30 83% Pupillary block 
in 1 patient
Total   C3F8 93 83%
Complication 
in 3 patients (3.2%)
ARMD = age related macular degeneration; ERM = epiretinal membrane; PRDR = proliferative diabetic retinopathy; PVD = posterior 
vitreous detachment; VMA = vitreomacular adhesion; VMT = vitreomacular traction; WVMAT = width of vitreomacular attachment
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4.6%; in about two-thirds of phakic eyes, cataract de-
velops within 2 years of surgery7.
Since 2012, ocriplasmin has been approved as a 
non-surgical, pharmacologic agent for the treatment 
of symptomatic VMT, but vitreolysis is only achieved 
in 25%-50%8,9, with a high incidence of side eff ects8 
and at a high cost.
In the last years, pneumatic vitreolysis has started 
to show promise as a new treatment option for VMT.
In the past two decades, there have been quite a 
few studies investigating the effi  cacy of a single intra-
vitreal gas injection in causing PVD in eyes with dif-
ferent pathologies, such as nonproliferative diabetic 
retinopathy10, diabetic macular edema11, stage II macu-
lar holes12, and wet macular degeneration13. Th e suc-
cess rate was 95%-100% with very few complications.
Recently, at least three small case studies investi-
gated pneumatic vitreolysis also in eyes with VMT. 
Rodrigues et al. demonstrated that a single intravitreal 
injection of perfl uoropropane (C3F8) could cause 
VMT resolution in 5/7 (70%) eyes with isolated VMT 
and in 3/6 (50%) eyes with concurrent diabetic macu-
lar edema14. Th ere were no complications. Day et al. 
obtained VMT release in 5/9 (55.6%) patients after a 
single intravitreal injection of sulfur hexafl uoride 
(SF6). A peripheral retinal tear occurred in one patient 
(11%), and no other complications were noted15. In a 
study more recently published by Steinle et al., com-
plete release after intravitreal injection of up to 0.3 mL 
of 100% C3F8 occurred in 25 out of 30 eyes (83%) 
with symptomatic VMT. Th ey had the same success 
rate in eyes with concurrent epiretinal membrane 
(ERM) (5 out of 6 eyes, 83%) and in eyes previously 
treated with ocriplasmin (5 out of 6 eyes, 83%)16. Ac-
cording to these studies, a single intravitreal gas injec-
tion seems to be effi  cacious in causing PVD and could 
therefore be a promising treatment option for VMT 
with a high success rate and very high safety profi le. 
However, the total number of patients and the power 
of studies were rather low. In most of the studies, ei-
ther SF6 or C3F8 was used, and hexafl uoroethane 
(C2F6) was also used in one study17.
Table 1 presents specifi c and combined success 
rates achieved in the studies using SF6 or C3F8. SF6 
was used in a total of 29 eyes and PVD was obtained 
in 78% of cases. C3F8 was used in 93 eyes in total, 
with PVD occurring in 83% of cases.
According to these studies, intravitreal SF6 and 
C3F8 injections seem to be almost equally effi  cacious 
in causing PVD, even though they have diff erent spe-
cifi c qualities. A pure SF6 bubble expands to about 
double the volume injected within 24 to 48 hours, and 
stays in the eye for 1 to 2 weeks. A pure C3F8 bubble 
expands to about 4 times its original volume within 72 
to 96 hours, and persists in the vitreous cavity for 6 to 
8 weeks. Since SF6 is reabsorbed from the vitreous 
much faster and it is much less of a burden for the 
patient, we wanted to check whether, despite its lower 
expansibility, it is really as eff ective in releasing VMT 
as C3F8.
Th e purpose of our study was to directly compare 
the effi  cacy of intravitreal injections of SF6 and C3F8 
in causing PVD, and additionally to evaluate the vi-
sual acuity success rate after pneumatic PVD in pa-
tients with VMT. 
Patients and Methods
Th is prospective comparative study included 57 
eyes of consecutive patients aged 57-91 years with 
symptomatic VMT and primary FTMH stage II. Pa-
tient enrolment and treatment took place at the Eye 
Hospital of the University Medical Center Ljubljana. 
Preoperatively and postoperatively, the routine com-
prehensive ophthalmological examination (including 
best corrected visual acuity (BCVA) using Snellen 
charts, biomicroscopy and funduscopy) and spectral 
domain OCT (SD-OCT) of the macula were per-
formed with Heidelberg Spectralis in all patients.
Th e width of vitreomacular attachment (WV-
MAT), central retinal thickness (CRT), integrity of 
external limiting membrane (ELM) and ellipsoid 
zone, and the presence of ERM were noted. Postop-
eratively, we looked for the presence of PVD; restora-
tion of foveal contour and CRT were noted.
Th e inclusion criteria were any symptomatic VMT 
with deterioration of visual acuity of at least 2 Snellen 
lines and the duration of symptoms for at least 3 
months (or less if the deterioration was very rapid, at 
least 2 or more Snellen lines in 0.5 months), and pri-
mary FTMH stage II according to Gass.
Th e only exclusion criterion were completely dis-
rupted outer retinal layers on OCT.
Twenty-nine eyes from the C3F8 group received a 
single intravitreal injection of 0.3 mL of 100% C3F8, 
and 28 eyes from the SF6 group received a single in-
travitreal injection of 0.3 mL of 100% SF6. Th e gas 
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was injected in an operating theatre under sterile con-
ditions. Paracentesis with aqueous humor leakage was 
performed right after the injection to release the intra-
ocular pressure. No medications were used intra- or 
postoperatively. Patients were then asked to nod their 
head occasionally in the next few days and/or hold 
prone position for a few consecutive minutes 5-10 
times a day. Follow-up visits were performed at week 
1, month 1, month 3 and month 6 after the injection.
Eyes from the SF6 group that showed no PVD on 
SD-OCT one month after the injection were rein-
jected with 0.3 mL of 100% C3F8. Th ey were followed 
by the same protocol.
Th e primary outcome was the ratio of eyes with 
complete VMT release on SD-OCT one month fol-
lowing the primary injection. Th e secondary outcome 
was the ratio of reinjected eyes with complete release 
on SD-OCT one month after the second injection.
Additional outcomes were the ratio of VMT re-
lease in eyes with diff erent WVMAT, CRT, integrity 
of external ELM, ellipsoid zone, and the presence of 
ERM.
T-test was used to compare preoperative character-
istics of the C3F8 and SF6 groups (age, WVMAT and 
CRT). Th e χ2-test was used to compare VMT release 
after one month between the C3F8 and SF6 groups 
and between the subgroups with specifi c clinical char-
acteristics.
Results
Th ere was no statistically signifi cant diff erence in 
age, WVMAT and CRT, or the presence of additional 
features between the two groups (Table 2).
One month after the application, complete release 
of VMT on SD-OCT was recorded in 18 out of 29 
eyes (62%) in the C3F8 group and in 6 out of 28 eyes 
(21.4%) in the SF6 group, yielding a statistically sig-
nifi cant diff erence (p=0.003). In the reinjected group, 
complete release of VMT demonstrated by SD-OCT 
one month after reinjection was recorded in 7 out of 
14 eyes (50%) (Fig. 1).
Most of the eyes with VMT release from both 
groups had VMT release already in the fi rst week (12 
out of 18 (66.6%) eyes from the C3F8 group and 5 out 
of 6 (83.3%) eyes from the SF6 group). In the rein-
jected group, PVD was noted after 1 week in only 2 
out of 7 (28.6%) eyes. In this group, another eye 
showed VMT release at the month 3 visit. No other 
Table 2. Comparison of patient clinical characteristics
Characteristic C3F8 group SF6 group p-value















No. of eyes with ERM/all eyes (%) 10/29 (34.5%) 9/28 (32.1%) 1.000
No. of eyes with CME/all eyes (%) 21/29 (72.4%) 25/28 (89.2%) 0.179
No. of eyes with FTMH /all eyes (%) 4/29 (13.8%) 0/28 (0%) 0.112
No. of eyes with subretinal fl uid/all eyes (%) 6/29 (20.6%) 3/28 (10.7%) 0.470
No. of pseudophakic eyes/all eyes (%) 10/29 (34.5%) 8/28 (28.6%) 0.777
CME = cystoid macular edema; CRT = central retinal thickness; ERM = epiretinal membrane; FTHM = primary stage II 
full-thickness macular hole; WVMAT = width of vitreomacular attachment
Fig. 1. Vitreomacular traction (VMT) release one month 
after gas injection.
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VMT release was noted in the additional 3-month 
follow-up period in either group.
In 4 eyes with preoperative stage II primary 
FTMH (160-310 microns, mean 223 microns) from 
the C3F8 group, VMT release occurred in 4/4 (100%) 
eyes. In one eye (25%), the hole closed; its size was 160 
microns. Th e other three patients proceeded to sur-
gery; the hole was successfully closed after fi rst vitrec-
tomy.
Table 3 shows the ratio of VMT release in groups 
of eyes with specifi c clinical characteristics. Th e effi  -
cacy in VMT release in narrower WVMAT was simi-
lar in both groups; however, intravitreal C3F8 injec-
tion was more effi  cacious than SF6 in releasing VMT 
in eyes with WVMAT larger than 500 microns 
(p=0.001). In the ERM subgroup, VMT release was 
present in 2/10 (20%) eyes after C3F8 and in none 
after SF6 injection.
3.6%). Th ree patients proceeded to vitrectomy, in all 
the retina was attached and macular hole closed after 
fi rst vitrectomy. One patient declined the operation. 
No other signifi cant complications were observed.
Discussion
In our group of eyes, complete VMT release was 
achieved in 62% of eyes with a single intravitreal injec-
tion of 0.3 mL of 100% C3F8 and with the same vol-
ume of 100% SF6 only in 21.4% of eyes. Since there 
was no statistically signifi cant diff erence in the preop-
erative features between the two gas groups, this result 
alone implies that C3F8 is more effi  cacious in releas-
ing VMT than SF6. Obtaining PVD with secondary 
intravitreal C3F8 injection in 50% of eyes that failed 
to respond to primary injection with SF6 backs up this 
implication.
Analyzing the eff ect of the two gases on VMT re-
lease according to WVMAT, C3F8 and SF6 were 
equally eff ective in the narrower width of attachment 
(<500 microns, p=0.4410), while C3F8 was much 
more eff ective than SF6 in releasing VMT in the 
group with greater WVMAT (>500 microns, p=0.001). 
It also seemed to be more successful in eyes with 
ERM; with the intravitreal injection of SF6 we did not 
achieve a single release in this subgroup.
According to the literature, our study that included 
57 eyes seems to be the largest one investigating pneu-
matic vitreolysis so far. It was also the fi rst study di-
rectly comparing the effi  cacy of the two gases (SF6 
and C3F8). Th e number of eyes was large enough to 
prove that C3F8 in general was superior to SF6 in 
 releasing VMT and equally eff ective in narrower 
WVMAT.
Comparison of our results and those reported from 
other studies investigating pneumatic vitreolysis in 
eyes with diff erent pathologies10-16 reveals that we had 
a lower overall PVD rate with either gas injection. In 
these studies, PVD was achieved in 56%-100% (mean 
78%) with SF6 and in 40%-100% (mean 83%) with 
C3F8. Th is may be due to the less narrow patient se-
lection in our study; the included patients were con-
secutively recruited patients that met the inclusion 
criteria notwithstanding the WVMAT or any of the 
additional features. Certain clinical characteristics 
such as patient age11,15,16 and phakic/pseudophakic ra-
tio15,16 were, to our knowledge, similar to other studies, 
Table 3. VMT release ratio after gas injection in groups of 
eyes with specifi c clinical characteristics
 
Number of eyes with VMT 
release/all eyes (percentage 
of VMT release) 
p-value
C3F8 group SF6 group
Epiretinal 
membrane
2/10 (20.0%) 0/9 (0%) 0.4737
WVMAT
1000-3500 μm
2/6 (33.3%) 0/2 (0%) 1.000
WVMAT
500-1000 μm
5/7 (71.4%) 0/14 (0%) 0.001
WVMAT
>500 μm 
7/13 (53.8%) 0/16 (0%) 0.001
WVMAT
<500 μm
11/16 (68.6%) 6/12 (50%) 0.4410
VMT = vitreomacular traction; WVMAT = width of vitreomacular 
attachment
Considering complications, there was a peripheral 
retinal tear with localized retinal detachment in one 
eye and a small FTMH with a diameter of 220 mi-
crons in another eye seen one week after C3F8 injec-
tion. After one month, another eye with a macular hole 
of 330 microns was found in this group (complication 
rate: 3/29 eyes, 10.3%). A small macular hole with a 
diameter of 225 microns was also found in one eye 
from the SF6 group at one-week follow-up (1/28 eyes, 
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but unfortunately, many of the previous studies failed 
to provide data on WVMAT and presence of ERM, so 
these characteristics could not be compared.
Th e reason for this PVD success rate diff erence 
may as well lie in the lower number of patients in pre-
vious studies or in diff erent vitreoretinal pathology. It 
is reasonable to believe that the strength of adhesion in 
eyes with VMT is much fi rmer than in eyes with VMA 
(which by defi nition is without vitreal traction) and 
could therefore explain the lower rate of pneumatically 
induced PVD in eyes with VMT. When comparing 
our results only with those from the studies investigat-
ing eyes with VMT14-16, we were equally eff ective, at 
least with C3F8. PVD rate in those studies was 40%-
84% (mean 61.5%), whereas in ours it was 62%.
Day et al. obtained PVD in 56% of eyes with VMT 
with the intravitreal injection of SF615, compared to 
our 21.4%, but they had only 9 eyes and in all 5 eyes 
with postoperative PVD WVMAT was less than 521 
microns and none had ERM.
In our study, C3F8 appeared to be superior to SF6 
also in the subgroup with ERM but the numbers were 
too small to prove it statistically signifi cant. Our re-
sults are comparable to previous studies, even though 
the number of eyes included in those studies was also 
very low. Day et al. had 2 eyes with ERM, and none 
had PVD after intravitreal SF615. On the other hand, 
Steinle et al. had 6 eyes with ERM and achieved PVD 
in 5 of those with intravitreal C3F816.
In our study, 4 eyes with primary stage II FTMH 
(160-310 microns, mean 223 microns) were included 
in the C3F8 group. PVD was obtained in 4/4 (100%) 
eyes, but only in one the hole closed (25%). Its size was 
160 microns, while the size of the hole in the remain-
ing three eyes was >200 microns. All patients with the 
remaining hole proceeded to surgery and the hole was 
successfully closed after fi rst vitrectomy.
Steinle et al. had 3 stage II FTMH; in 2 (66.6%), 
the hole closed after PVD16. Mori et al. had similar 
success12; they had 20 patients with stage II FTMH, in 
50% the hole closed after PVD. Th e size of the hole in 
all patients from both studies was less than 200 mi-
crons. Concluding from these data, the size of the hole 
being less than 200 microns may be an important 
prognostic factor for hole closure after successful 
pneumatic PVD in primary stage II FTMH.
Most of our patients from the SF6 group presented 
with a very small bubble or even no gas at all at the fi rst 
follow-up (week 1). In all these eyes, gas was absent at 
the second follow-up (month 1). On the contrary, in 
most patients from the C3F8 group, gas was fi lling up 
to one-third of their vitreal cavity at the fi rst follow-up 
and in all at least a small bubble was present at the 
second follow-up. Unlike the SF6 patients, patients 
that received C3F8 were complaining immensely 
about the gas bubble interference with their vision. 
Th ey reported having troubles walking down the stairs, 
preparing their meals and reading. However, what they 
found most annoying, some of them even completely 
unbearable, was the duration of troubles. Th e average 
time for PVD to appear after the injection was 13 days 
in the study by Steinle et al.16. Since also in our study 
more than 60% of eyes with VMT release had PVD 
already one week after the injection, it seems that the 
effi  cacy of C3F8 might be more due to the expand-
ability rather than its persistence. We wonder would 
the results have been diff erent also in the subgroups 
with ERM or larger attachments if we had used 0.5 mL 
of 100% SF6 instead. Th e maximum expanded volume 
would then match that of C3F8 and might therefore 
exert the same eff ect, but with the advantage of faster 
clearance from the eye.
Ochoa-Contreras et al.10 used 0.5 mL of SF6 in 
their study on patients with nonproliferative diabetic 
retinopathy with a PVD success rate of 100%, but they 
had no ERM and unfortunately data on WVMAT are 
not provided in the published article.
Since according to previous studies and our own, it 
can now be said with certainty that gas injection is suf-
fi ciently eff ective in causing VMT release in eyes with 
WVMAT smaller than 1000 microns and in the ab-
sence of epiretinal membrane, we believe that due to its 
seemingly high safety profi le, low cost and easy accessi-
bility, it would seem reasonable in certain situations to at 
least try it as a fi rst line treatment in VMT patients that 
meet the above criteria. Th e waiting time for vitrectomy 
as a traditional way of treatment in some parts of the 
world exceeds six months. Postponing treatment for 
such a long time can result in photoreceptor damage 
and irreversible vision loss. Th e costs of vitrectomy vary 
in diff erent countries and hospitals, but generally 
amount to several hundred Euros. Intravitreal gas injec-
tion, on the other hand, can be applied at an offi  ce visit 
in just a few minutes and at minimal cost.
We suggest using SF6 in eyes with WVMAT 
smaller than 500 microns and C3F8 in those with 
WVMAT larger than 500 microns.
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Conclusion
According to the results of our study, intravitreal 
C3F8 injection appears to be as effi  cacious as SF6 in 
releasing smaller vitreomacular attachment and more 
effi  cacious in releasing larger vitreomacular attach-
ment in eyes with VMT.
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Sažetak
INTRAVITREALNO INJEKTIRANJE PERFLUOROPROPANA JE UČINKOVITIJE 
OD SUMPORNOG HEKSAFLUORIDA U OTPUŠTANJU VITREOMAKULARNE TRAKCIJE
N. Čokl i M. Globočnik Petrovič
Cilj istraživanja bio je usporediti učinkovitost intravitrealne injekcije perfl uoropropana (C3F8) i sumpornog heksafl uori-
da (SF6) u otpuštanju vitreomakularne trakcije (VMT). Ova prospektivna studija uključivala je dvije skupine bolesnika sa 
simptomatskom VMT potvrđenom spektralnom optičkom koherentnom tomografi jom (spectral domain optic coherent tomo-
graphy, SD-OCT). Bolesnici obiju skupina primili su jednu intravitrealnu injekciju ekspanzibilnog plina. Jedna skupina (29 
očiju) primila je 0,3 mL 100%-tnog C3F8, a druga skupina (28 očiju) 0,3 mL 100%-tnog SF6. Kod očiju gdje otpuštanje 
VMT nije nastupilo jedan mjesec od injekcije SF6 primijenjena je dodatna injekcija C3F8. Primarni ishod bio je omjer  očiju 
u svakoj skupini s potpunim otpuštanjem VMT na OCT jedan mjesec od primarnog liječenja. Sekundarni ishod bio je omjer 
ponovno injektiranih očiju s potpunim otpuštanjem VMT na OCT jedan mjesec nakon druge injekcije. Dodatni ishod bio 
je omjer otpuštanja VMT kod očiju sa specifi čnim kliničkim obilježjima. Jedan mjesec od primjene lijekova potpuno otpu-
štanje VMT na OCT zabilježeno je u 18 od 29 (62%) očiju u skupini koja je primila C3F8, u 6 od 28 (21,4%) očiju u sku-
pini koja je primila SF6 te u 7 od 14 (50%) očiju s ponovljenom injekcijom. Između dviju skupina nije bilo statistički zna čajne 
razlike u dobi, širini vitremakularnog spoja (width of vitreomacular attachment, WVMAT), debljini središnje mrežnice i 
 prisutnosti dodatnih obilježja. Kod očiju s WVMAT <500 mikrona nije bilo statistički značajne razlike između dva plina 
u otpuštanju VMT. Kod očiju s WVMAT >500 mikrona C3F8 se pokazao učinkovitijim (p<0,001). Prema rezultatima 
ovoga istraživanja izgleda da je injekcija C3F8 učinkovitija od SF6 u otpuštanju VMT kod očiju s WVMAT većom od 500 
mikrona.
Ključne riječi: intravitrealne injekcije; retinalne bolesti; prospektivne studije; tomografi ja, optička koherentna; ishod zdravstve-
ne skrbi, ocjena
